Pathway candidateNCBI-verifiedprotein-coding

SLC7A5

solute carrier family 7 member 5

NCBI Gene: 8140 Ensembl GeneCards UniProt: Q01650

Pathway candidate — not linked to PFS or PSSD by any record here

SLC7A5 is in the library because it belongs to the drug transporters family. No study, report or commentary in the corpus names it, so a variant in SLC7A5 is not, by itself, evidence of anything related to post-drug syndromes.

Gene summary

A protein-coding gene on chromosome 16 (drug and xenobiotic transporters). Enables transmembrane transporter activity. Involved in carboxylic acid transport; thyroid hormone transport; and xenobiotic transport.

Source: NCBI Gene, accessed 2026-10-07.

Protein reference (UniProt)

Protein: Large neutral amino acids transporter small subunit 1
Function (excerpt): Forms a heterodimer with SLC3A2 that functions as a sodium-independent transporter for large neutral amino acids. Functions as an obligatory amino acid antiporter, mediating the exchange of amino acids and amino acid-related compounds across the plasma membrane. Also mediates sodium-independent exchange of iodothyronines with neutral and aromatic L-alpha-amino acids. Mediates exchange of L-tryptophan with the tryptophan metabolites L-kynurenine and 3-hydroxy-L-kynurenine. Mediates cellular uptake of iodothyronines, including thyroxine (T4), triiodothyronine (T3), reverse triiodothyronine (rT3) and 3,3'-diiodo-L-thyronine (3,3'-T2), and iodotyrosines including 3-iodo-L-tyrosine (MIT) and 3,5-diiodo-L-tyrosine (DIT). Involved in the uptake of methylmercury (MeHg) when administered as L-cysteine or D,L-homocysteine complexes, thereby contributing to metal ion homeostasis and toxicity.
Subcellular location: Apical cell membrane; Cell membrane; Lysosome membrane.
Tissue specificity: Detected in placenta, in the syncytiotrophoblast layer (at protein level). Expressed abundantly in adult lung, liver, brain, skeletal muscle, placenta, bone marrow, testis, resting lymphocytes and monocytes, and in fetal liver. Weaker expression in thymus, cornea, retina, peripheral leukocytes, spleen, kidney, colon and lymph node. During gestation, expression in the placenta was significantly stronger at full-term than at the mid-trimester stage. Also expressed in all human tumor cell lines tested and in the astrocytic process of primary astrocytic gliomas. Expressed in retinal endothelial cells and in the intestinal epithelial cell line Caco-2.

Source: UniProtKB/Swiss-Prot Q01650, release 2026_03, licensed CC BY 4.0. This is the protein’s normal biology, not evidence about post-drug syndromes; associated conditions are inherited disorders of the gene, not PFS, PSSD or PRSD.

Why its pathway is in the library

Transporters set systemic exposure to finasteride/SSRIs and clear conjugated steroid metabolites — directly relevant to both drug pharmacokinetics and Powers' clearance-centered PFS mechanism.

Written for the whole drug transporters family, not for SLC7A5 specifically.

Mentioned in 0 corpus records

No corpus record names SLC7A5 directly yet. It is in the library because it sits in a pathway the corpus tracks (Drug transporters).

Also in drug and xenobiotic transporters

All 62 genes

Browse by family on the gene families page.

Protein reference (UniProt)

Protein: Large neutral amino acids transporter small subunit 1
Function (excerpt): Forms a heterodimer with SLC3A2 that functions as a sodium-independent transporter for large neutral amino acids. Functions as an obligatory amino acid antiporter, mediating the exchange of amino acids and amino acid-related compounds across the plasma membrane. Also mediates sodium-independent exchange of iodothyronines with neutral and aromatic L-alpha-amino acids. Mediates exchange of L-tryptophan with the tryptophan metabolites L-kynurenine and 3-hydroxy-L-kynurenine. Mediates cellular uptake of iodothyronines, including thyroxine (T4), triiodothyronine (T3), reverse triiodothyronine (rT3) and 3,3'-diiodo-L-thyronine (3,3'-T2), and iodotyrosines including 3-iodo-L-tyrosine (MIT) and 3,5-diiodo-L-tyrosine (DIT). Involved in the uptake of methylmercury (MeHg) when administered as L-cysteine or D,L-homocysteine complexes, thereby contributing to metal ion homeostasis and toxicity.
Subcellular location: Apical cell membrane; Cell membrane; Lysosome membrane.
Tissue specificity: Detected in placenta, in the syncytiotrophoblast layer (at protein level). Expressed abundantly in adult lung, liver, brain, skeletal muscle, placenta, bone marrow, testis, resting lymphocytes and monocytes, and in fetal liver. Weaker expression in thymus, cornea, retina, peripheral leukocytes, spleen, kidney, colon and lymph node. During gestation, expression in the placenta was significantly stronger at full-term than at the mid-trimester stage. Also expressed in all human tumor cell lines tested and in the astrocytic process of primary astrocytic gliomas. Expressed in retinal endothelial cells and in the intestinal epithelial cell line Caco-2.